Photo © 2016 HOK

Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies took place October 13-15 at the Waldorf-Astoria Hotel in New York, New York.

Combine flow and HTS for sensitive MRD detection in CLL, speaker says

Print Friendly, PDF & Email


flow_cytometry_using_laser_beam_Credit_NIH_220_final.jpg
Flow cytometry using
laser beam
Photo courtesy of NIH

Combining 2 technologies—flow cytometry and high-throughput sequencing (HTS)—produces a very sensitive approach to detecting minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL), according to a speaker at Lymphoma & Myeloma 2016. The approach is both reproducible and widely accessible, added the speaker, Peter Hillmen, MB... [Read Article]

Print Friendly, PDF & Email

Rethinking testing in multiple myeloma

Print Friendly, PDF & Email


plasma_cells_malignant_240.jpg
Malignant plasma cells

As the number of therapeutic options for multiple myeloma (MM) increases, so too does the need to reassess prognostic markers for the disease, according to a speaker at Lymphoma & Myeloma 2016. “A good prognosticator for one patient may have little meaning for another patient,” said Scott Ely, MD, of Weill Cornell... [Read Article]

Print Friendly, PDF & Email

Genetic screening for CLL premature, speaker says

Print Friendly, PDF & Email


genome_testing_credit_National_Institute_of_General_Medical_Sciences-200.jpg
Genome testing
Photo courtesy of the
National Institute
of General Medical Science

Research has shown that family history is a strong risk factor for developing chronic lymphocytic leukemia (CLL). First-degree relatives have an 8.5-fold risk of getting CLL and an increased risk of other lymphoproliferative disorders, according to a study published in... [Read Article]

Print Friendly, PDF & Email

No longer a hand-me-down approach to WM

Print Friendly, PDF & Email


treon_steven_MD_PhD_Credit_DFCI_220.jpg
Steven Treon, MD, PhD
Photo courtesy of DFCI

Whole-genome sequencing has changed the entire approach to drug development for Waldenström’s macroglobulinemia (WM), according to a speaker at Lymphoma & Myeloma 2016. The strategy has changed from a hand-me-down one, relying on drugs developed first for other diseases, to a rational plan designed specifically to treat... [Read Article]

Print Friendly, PDF & Email

Speaker says use the best regimen ASAP in MM

Print Friendly, PDF & Email


multiple_myeloma_240.jpg
Multiple myeloma cells

It’s important to use the best possible regimen as soon as possible when treating patients with multiple myeloma (MM), according to a speaker at Lymphoma & Myeloma 2016. Antonio Palumbo, MD, of the University of Torino in Italy, explained that the urgency, from a biological point of view, is because myeloma accumulates... [Read Article]

Print Friendly, PDF & Email

Doc provides perspective on CAR T-cell therapy in CLL

Print Friendly, PDF & Email


CTL019_Penn_Medicine_230.jpg
The CAR T-cell therapy CTL019
Photo from Penn Medicine

Trial data on the use of chimeric antigen receptor (CAR) T cells in chronic lymphocytic leukemia (CLL) are maturing, and a speaker at Lymphoma & Myeloma 2016 provided some perspective on the therapy as it now stands. Stephen J. Schuster, MD, of the University of Pennsylvania... [Read Article]

Print Friendly, PDF & Email